About Technology Issues FAQ

Links

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.